Amdoxovir

From Wikipedia, the free encyclopedia

Amdoxovir
Systematic (IUPAC) name
[(2R,4R)-4-(2,6-Diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
Identifiers
CAS number  ?
ATC code  ?
PubChem 124088
Chemical data
Formula C9H12N6O3 
Mol. mass 252.23 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Amdoxovir is an nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV. It is being developed by RFS Pharma.[1] Currently, it is in Phase II clinical studies.

[edit] References

  1. ^ AIDSmeds.com - Amdoxovir. Retrieved on 2008-03-21.


Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Abacavir (ABC)° • Emtricitabine° • Lamivudine (3TC)° • Tenofovir° • Didanosine • Zidovudine (AZT) • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Amdoxovir† • Stavudine‡ • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Protease Inhibitors (PI)
Entry/fusion inhibitors
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent.
Languages